64B16-28.850: Special Pharmacy - ESRD
PURPOSE AND EFFECT: The Board proposes the rule amendment to add additional drugs to the rule.
SUMMARY: Additional drugs will be listed in the rule.
SUMMARY OF STATEMENT OF ESTIMATED REGULATORY COSTS: No Statement of Estimated Regulatory Cost was prepared.
Any person who wishes to provide information regarding a statement of estimated regulatory costs, or provide a proposal for a lower cost regulatory alternative must do so in writing within 21 days of this notice.
SPECIFIC AUTHORITY: 465.005, 465.0125 FS.
LAW IMPLEMENTED: 465.0196, 465.022 FS.
IF REQUESTED WITHIN 21 DAYS OF THE DATE OF THIS NOTICE, A HEARING WILL BE SCHEDULED AND ANNOUNCED IN FAW.
THE PERSON TO BE CONTACTED REGARDING THE PROPOSED RULE IS: Rebecca R. Poston, Executive Director, Board of Pharmacy/MQA, 4052 Bald Cypress Way, Bin #C04, Tallahassee, Florida 32399-3253
THE FULL TEXT OF THE PROPOSED RULE IS:
64B16-28.850 Special Pharmacy – ESRD.
(1) through (2) No change.
(3) Schedule of legend drugs:
(a) Saline Solutions.
(b) Porcine Heparin.
(c) Beef Heparin.
(d) Dextrose Solutions.
(e) Doxercalciferol.
(f) Epoetin Alfa.
(g)(e) NACL INJ 50 MEQ/20 ML.
(h) Levocarnitine.
(i)(f) Lidocaine.
(j)(g) Vitamin Preparations (dialysate use only).
(k) Paricalcitrol.
(l)(h) Peritoneal Dialysate Solutions.
(m)(i) Protamine Sulfate.
(n)(j) Potassium 20 MEQ/10ML (dialysate use only).
(o) Sodium Ferric Gluconate Complex or equivalent.
(p)(k) Sterile Water for Irrigation.
(4) through (17) No change.
Specific Authority 465.005, 465.0125 FS. Law Implemented 465.0196, 465.022 FS. History–New 10-2-94, Formerly 59X-28.850, Amended 9-20-99, 7-17-05,__________.